Haematology - Lymphoma & CLL Trials

A LIST OF OUR EARLY PHASE Haematology (Lymphoma & CLL) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

BP41072 An Open-Label, Phase I Study To Evaluate The Safety, Pharmacokinetics And Preliminary Antitumor Activity Of Ro7227166 (A Cd19 Targeted 4-1bb Ligand) In Combination With Obinutuzumab And Incombination With Ro7082859 (Cd20-Tcb) Following A Pre-Treatment Dose Of Obinutuzumab Administered In Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.
Local Project Reference:	129333
Principal Investigator:	Dr. William Townsend
Drug Class/ Treatment:	Ro7227166 (CD19-directed 41BB ligand) + Obinutuzumab (anti-CD20 Monoclonal Antibody) or Glofitamab (CD3-CD20 T-Cell Bispecific Antibody)
Patient Population:	Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

NVG111-101 NVG111-101: An open-label, phase 1/2, first in human study investigating the safety, tolerability, pharmacokinetics and efficacy of NVG-111 in subjects with relapsed/refractory chronic lymphocytic leukaemia and mantle cell lymphoma.
Local Project Reference:	135715
Principal Investigator:	Dr. William Townsend
Drug Class/ Treatment:	NVG-111 (Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) Bispecific Antibody)
Patient Population:	Relapsed or Refractory Chronic Lymphocytic Leukaemia & Mantle Cell Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

NP39488 Phase 1B RO7082859 & Atezolizumab in Non-Hodgkin's Lymphoma: AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA Sub-Study protocol: AN OPEN-LABEL, MULTI-CENTER, PHASE IB IMAGING SUB-STUDY OF GLOFITAMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) USING 89ZR-DF-IAB22M2C ASCD8 TRACER IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
Local Project Reference:	18/0377
Principal Investigator:	Dr. William Townsend
Drug Class/ Treatment:	RO7082859 (T-Cell Bispecific Antibody) + Atezolizumab (Monoclonal Antibody)
Patient Population:	Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

LOTIS-7 ADCT-402-105 ADCT-402-105/LOTIS7: A Phase lb Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Local Project Reference:	143220
Principal Investigator:	Dr. William Townsend
Drug Class/ Treatment:	Loncastuximab Tesirine (Monoclonal Antibody Conjugate Targeting CD19) In Combination with other anti-cancer agents. Arm C – Loncastuximab tesirine + Polatuzumab vedotin
Patient Population:	Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

JCAR017-FOL-001 TRANSCEND FL Hodgkins Lymphoma-0451/0497-Celgene Corporation: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL).
Local Project Reference:	128476
Principal Investigator:	Dr. Kirit Ardeshna
Drug Class/ Treatment:	JCAR017 (CD19-Directed 4-1bb CAR T Cell Therapy)
Patient Population:	Relapsed or Refractory: Follicular Lymphoma (FL) Marginal Zone Lymphoma (MZL)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

CAROUSEL Immunotherapy using CAR T-cells to target CD19 for relapsed/refractory CD19+ Primary CNS Lymphoma
Local Project Reference:	126892
Principal Investigator:	Dr. Claire Roddie
Drug Class/ Treatment:	CD19CAR (CD19 CAR T-Cell Therapy)
Patient Population:	Relapsed/Refractory Primary CNS Lymphoma ≥16 Years Dld
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

KEYNOTE 667 MK3475-667: An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667).
Local Project Reference:	127624
Principal Investigator:	Dr. Stephen Daw
Drug Class/ Treatment:	Pembrolizumab (PD-1 Inhibiting Monoclonal Antibody) Chemotherapy with the AVBD drug regimen or OEPA drug regimen. Slow early responders to chemotherapy will be treated with Pembrolizumab and chemotherapy: either the AVD drug regimen or COPDAC-28 drug regimen.
Patient Population:	Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy. CYA aged 3 - 25 Years Old
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ALLCAR19 Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)
Local Project Reference:	16/0530
Principal Investigator:	Dr. Claire Roddie
Drug Class/ Treatrment:	CAR T-Cell Therapy Expressing CD19 Chimeric Antigen Receptor (CD19CAR)
Patient Population:	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) Chronic Lymphocytic Leukaemia (CLL) Small Lymphocytic Lymphoma (SLL) Adults >/=16 years old
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

AUTO4-TL1 Phase I/II study - AUTO4 in patients with T cell non-Hodgkin Lymphoma : A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T Cell Treatment Targeting TRBC1, in Patients with Relapsed or Refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma.
Local Project Reference:	17/0680
Principal Investigator:	Dr. Kate Cwynarski
Drug Class/ Treatrment:	AUTO4 - CAR T-Cell Therapy Targeting TRBC1
Patient Population:	Relapsed or Refractory TRBC1 positive selected T Cell Non-Hodgkin Lymphoma.
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

NAVAL-1 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Local Project Reference:	140945
Principal Investigator:	Dr. Kirit Ardeshna
Drug Class/ Treatrment:	Nanatinostat (Histone Deacetylase Inhibitor) + Valganciclovir (Antiviral Medication)
Patient Population:	Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

PRiZM+ PRiZM+: A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma
Local Project Reference:	144707
Principal Investigator:	Dr. Kate Cwynarski
Drug Class/ Treatrment:	Zanubrutinib (Bruton Tyrosine Kinase Inhibitor) Monotherapy and Combination Therapy
Patient Population:	Relapsed and Refractory Primary CNS Lymphoma
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

Principal Investigator(s):

Dr. william townsend

Consultant Haematologist